Prohost Biotech
HomeArticlesToday's HighlightsAdaptimmune Data From Phase I/II Trial Demonstrate Safety and Efficacy
Today's Highlights
Premium

Adaptimmune Data From Phase I/II Trial Demonstrate Safety and Efficacy

ADAPTIMMUNE (ADAP) Data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published...
P

Prohost Biotech

1 min read
17
0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles
Expert analysis
Research reports

Tags

AdaptImmune Therapeutics (ADAP)

Comments (0)

Please sign in to join the discussion

Related Articles

Today's Highlights
Premium

Lilly to acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders

Eli Lilly & Centessa Pharmaceuticals Story March 31, 2026 /PRNewswire/ -- Eli Lilly and Company ( LLY ) and Centessa Pharmaceuticals plc ( CNTA ) announced a definitive agreement for Lilly to acquire...
P

Prohost Biotech

Mar 31, 2026

1m
85
Today's Highlights
Premium

Biogen: FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Biogen in the NEWS Today,  March 30, 2026, Biogen Inc ( BIIB ) announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by th...
P

Prohost Biotech

Mar 30, 2026

1m
77
Today's Highlights
Premium

Rocket Pharmaceuticals Announced FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I

Rocket Pharmaceuticals in the NEWS March 27, 2026, Rocket Pharmaceuticals ( RCKT ) announced that the U.S. FDA has granted accelerated approval for KRESLADI™ (marnetegragene autotemcel), an autologous...
P

Prohost Biotech

Mar 27, 2026

1m
61